Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State
Phase 1
Completed
- Conditions
- Hepatitis C Virus
- Interventions
- Drug: Pharmacokinetics
- Registration Number
- NCT00861458
- Lead Sponsor
- Pfizer
- Brief Summary
This study will test two different formulations. The results will be used to select formulation for phase 3.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
- Healthy volunteers.
Exclusion Criteria
- Standard for healthy volunteers.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description PF-00868554 Pharmacokinetics -
- Primary Outcome Measures
Name Time Method AUC inf, Cmax 2 days
- Secondary Outcome Measures
Name Time Method Adverse events 2 days
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇧🇪Bruxelles, Belgium